# Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)

> **NCT00953615** · PHASE2 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 1 (actual)

## Conditions studied

- Primary Sclerosing Cholangitis

## Interventions

- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT00953615
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-04
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2012-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00953615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00953615, "Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00953615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*